Key points are not available for this paper at this time.
Background: F]FDG-PET findings and CSF AD biomarkers in a real-world tertiary memory clinic setting. Methods: F]FDG-PET was compared with gold-standard CSF AD biomarkers using kappa agreement test and regression models. Findings: = 0.0016). Interpretation: F]FDG-PET report and CSF AD biomarker results was only fair. Funding: NR-L was supported by a Research Fellowship from the Fundación Ramón Areces, Madrid (Spain). JC, BCD, SEA, PK, and AS-P were supported by the Massachusetts Alzheimer's Disease Research Center (NIH/NIA P30AG062421).
Rabaneda‐Lombarte et al. (Mon,) studied this question.